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Abstract
This review discusses recent findings that have challenged the long-held dogma in the
field that reduction in reaction oxygen species (ROS) would improve clinical outcome
in the patients with cardiovascular disease (CVD). Attempts will be made to shed light
on the differential spatial and temporal roles of subcellular ROS in vascular endotheli-
um in health and disease.  Recent  findings demonstrating that  above-physiological
levels  of  endothelial  cell  (EC)-specific  NADPH  oxidase-derived  ROS  in  vivo  exert
beneficial effects on vascular endothelium will be discussed. The paradoxical roles of
ROS in CVD suggest that subcellular sources and types of ROS may play crucial roles
in the prevention, development, and progression of CVD. A better understanding of
the precise mechanisms by which subcellular ROS modulate cardiovascular health and
functions will certainly better prepare us with effective treatment modalities for CVD.
Keywords: reactive oxygen species, cardiovascular disease, endothelium, oxidative
stress, signal transduction
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in the USA. Increased levels of
reactive oxygen species (ROS) are often associated with microvascular pathology in CVD,
causing endothelial dysfunction and coronary artery disease (CAD) and leading to myocar-
dial  ischemia  and  infarction  (MI)  [1–5].  However,  failure  of  large  clinical  trials  using
antioxidants in patients with CVD [6–11], challenges the prevailing view that ROS produc-
tion is damaging to the microvasculature. Indeed, findings from our laboratory and others
show negative effects of ROS reduction on endothelial function and angiogenesis [12–14]
and suggest  that  a  well-regulated temporal  balance of  ROS production is  important  for
normal endothelial cell (EC) function.
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The paradoxical roles of ROS in CVD studied by different groups of workers also suggest that
subcellular sources and types of ROS may also play crucial roles in the prevention, develop-
ment, and progression of CVD. This review discusses recent findings that are challenging the
long-held dogma in the field and also attempts to shed light on the differential spatial and
temporal roles of subcellular ROS in vascular endothelium in CVD. A better understanding of
the precise mechanisms by which subcellular ROS modulate cardiovascular health and
functions will certainly better equip us with effective treatment modalities for CVD in future.
2. Cardiovascular disease (CVD)
Cardiovascular disease (CVD) is a leading cause of death and morbidity in the Western world.
Recent reports suggest an increasing incidence of CVD in the developing countries too. In the
USA, CVD with an annual toll of 1.2 million lives is the leading cause of deaths since 1921. At
present, 85.6 million people in the country are living with CVD. In 2015, American Heart
Association (AHA) reported that the prevalence of CVD among US adults is 6% with a
calculated financial burden of $300 billion per year [15].
Vascular endothelium is critical for the optimal function of the heart and the vascular system,
in particular due to its production of nitric oxide (NO) that regulates vascular tone and blood
pressure (Figure 1). By regulating vascular tone including coronary vasodilation, NO plays
an important role in blood supply to the myocardium (by coronary vessels) and other tissues
in the body. Damage to coronary endothelium results in reduction in NO levels by reducing
the level and/or activity of the enzyme, endothelial nitric oxide synthase (eNOS). This in turn
contributes to the development of endothelial dysfunction (i.e. loss of vasodilation) and
coronary artery disease (CAD), which may lead to ischemic insult to the heart including
myocardial infarction and heart failure (HF). In myocardial ischemia, coronary vasodilation
is an immediate response that may improve coronary blood flow in the heart. Another potent
way myocardium employs to defend itself from ischemic insults is by preserving the existing
coronary capillary vessels and/or by inducing growth of coronary vessels in the ischemic area
[16–18]. Once the ischemic insult has occurred, survival of the affected cardiac tissue depends
on the speed with which coronary vessels can increase blood flow. Thus, a functional coronary
vascular system with endothelium-dependent NO-induced vasodilation mechanism is critical
for the maintenance of coronary vascular health in the heart. Endothelial health and NO levels
are also critical for the maintenance of blood pressure and prevention of hypertension that is
an important risk factor for CVD.
Another major contributor to CVD is atherosclerosis, which is characterized by the accumu-
lation of inflammatory leukocytes and lipid-laden macrophages in the vascular wall resulting
in the gradual narrowing of the vascular lumens and wall thickness (Figure 1A). These changes,
if generalized, result in arterial stiffness and can give rise to high blood pressure (hyperten-
sion); if the changes are localized, they may result in blocking of blood flow (ischemia and
peripheral arterial disease), and in more severe cases, they may result in myocardial infarction,
cerebrovascular disease/accident (stroke), atherosclerotic plaque rupture, and/or weakening
of the vessel walls (aneurysm) (Figure 1).
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Figure 1. (A) Vascular endothelium performs critical functions in cardiovascular system, including nitric oxide (NO)-
dependent vasodilation, maintenance of blood fluidity by preventing breach in the EC layer and platelet aggregation,
NO-mediated inhibition of vascular smooth muscle cell (VSMC) proliferation and neointima formation, and inhibition
of leukocyte adhesion to EC. Pathogenesis that may occur due to lack of specific function of EC is shown inside the
circle. EC, endothelial cell; VSMC, vascular smooth muscle cell; and eNOS, endothelial nitric oxide synthase. (B) Nitric
oxidase (NO)-mediated vasodilatation and other critical functions of vascular endothelium can be inhibited or blocked
by excess ROS, specifically by superoxide. Endothelial nitric oxide synthase (eNOS) produces NO that acts on the lu-
minal surface of the endothelium to prevent leukocyte adhesion and platelet aggregation/coagulation. NO diffuses to
adjacent vascular smooth muscle layer (VSMC) to activate cyclic GMP (cGMP) signaling resulting in calcium ion re-
lease and relaxation of VSMC. All these NO functions can be blocked or reduced by the presence of excess ROS in the
vascular wall.
Metabolic syndrome characterized by hypertension, obesity, glucose intolerance (diabetes),
and hyperlipidemia is often accompanied by CVD. The endothelial dysfunction associated
with metabolic syndrome has also been shown to have diminished angiogenic response and
aberrant collateral vessels to chronic myocardial ischemia in large animal model [19, 20].
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CVD including hypertension and heart failure (HF) are the most common cause of mortality
in diabetes mellitus (DM) and usually result from DM-induced cardiomyopathy and CAD.
The Framingham study showed that patients with DM are four times more likely to develop
CVD. The worldwide prevalence of DM has recently been reported to be increased (total DM
patients in 2015 have been projected to be over 300 millions) due to changes in lifestyle.
3. ROS and CVD cohabitation
Reactive oxygen species (ROS) has long been implicated in CVD. Increased levels of ROS are
often observed in vascular tissues including coronary endothelium in CVD, and thus are
believed to cause coronary endothelial dysfunction, CAD, myocardial ischemia, and infarc-
tion [1–5]. Although the mechanisms by which ROS may cause CVD has not been elucidated,
increased levels of ROS, also known as oxidant stress, are believed to arise from endothelial
cells (EC) resulting in loss of EC-dependent vasorelaxation and EC injury (Figure 1B). Oxidant-
induced injury in EC in turn may result in recruitment of the inflammatory cells in the vessel
wall leading to a cascade of vascular injuries. Dysfunctional EC leads to remodeling of the
vascular tissues such as accelerated proliferation of the underlying vascular smooth muscle
cells resulting in neointimal hyperproliferation/thickening and narrowing of the vessel lumen/
stenosis (Figure 1). Vascular stenosis results in tissue ischemia and may also be complicated
with thrombus formation. In the presence of hyperlipidemia, injury to EC may contribute to
atherosclerotic changes. Remodeling of vessel wall, depending on the vascular bed affected
and associated pathology/comorbidity, may result in hypertension, pulmonary hypertension,
diabetic retinopathy, peripheral artery disease, myocardial ischemia, and stroke.
Interestingly, recent reports from several groups of workers demonstrated that reduction in
ROS did not improve EC function and/or angiogenesis [12, 13, 21]. These findings challenged
the long-held dogma that ROS are harmful and/or causative factor for developing CVD. More
recently, our laboratory has shown that EC-specific increase in ROS resulted in the improve-
ment of EC function and EC-dependent coronary vasodilation in transgenic animals [22]. All
these imply that cohabitation of ROS and CVD may not be simply concluded to have delete-
rious effects on cardiovascular system. In addition, failure of the clinical trials (e.g. HOPE) to
improve CVD using antioxidants and recent reports of beneficial effects of ROS on EC function
warrant careful studies to delineate the spatial and temporal roles of ROS at the subcellular
levels.
3.1. Types of ROS
ROS are reactive molecules that contain oxygen, they include molecules that have unpaired
electrons, such as superoxide (O2•−), hydroxyl anion (HO−), and nitric oxide (NO−) or that have
the oxidizing ability but do not possess free electrons, such as hydrogen peroxide (H2O2),
hypochlorous acid, and peroxynitrite (ONOO−).
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3.1.1. Superoxide
It is produced usually as part of the metabolic processes by many intracellular enzymes
such as NADPH oxidases (Nox), mitochondrial electron chain transport (ETC) system, Xan-
thine oxidase (XO), cytochrome P450, xanthine oxidase, lipoxygenase, myeloperoxidase, and
uncoupled eNOS. O2•− is highly reactive and thus very unstable and has a short lifespan. It
cannot cross cellular membranes and thus has a limited “area of action.” Superoxide is usu-
ally converted to H2O2 spontaneously or can be metabolized to H2O2 by the antioxidant en-
zyme superoxide dismutases (SODs).
3.1.2. Hydrogen peroxide
As aforementioned, H2O2 is usually produced by dismutation of O2•− by SOD or by metal
ions spontaneously in the Fenton reaction. Recently, Nox4 has been reported to be a source
for H2O2; it has been reported that major ROS emanates from Nox4 enzyme is most likely
H2O2 [23]. In comparison to superoxide, H2O2 is stable and can cross biological membranes,
the properties that make this ROS a major player in cell signal transduction mechanisms.
Figure 2. Reversible oxidation of thiol on cysteine residues modulate activity of the signaling molecules (kinases, phos-
phatases, and enzymes). NAPDH oxidase-derived ROS reversibly oxidize cysteine thiol (SH) to sulfenic acid (-SOH)
on c-Src, which in turn facilitates interaction between c-Src and VEGFR2 resulting in the activation of downstream
PI3K-Akt-eNOS signaling pathway in coronary endothelial cells (ECs). VEGF, vascular endothelial growth factor;
VEGFR2, VEGF receptor 2; PI3K, phosphoinositol 3 kinase; Akt, protein kinase B; eNOS, endothelial nitric oxidase syn-
thase; and Src, c-Src.
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Due to its stability and membrane-crossing properties, H2O2 may act farther from its site of
origin. H2O2 can react with thiol (SH) residues present on cysteine and methionine, and can
catalyze the formation of the disulfide bonds (S-S) and reversible sulfenic acid (-SOH) and
sulfinic acid (-SO2H) moieties. All these changes can be reversed by antioxidant enzymes
such as glutathione peroxidase (Gpx). However, these changes, if involves the catalytic site
of the protein, can significantly modulate (activate, increase, decrease, or inhibit) the func-
tional properties of an enzyme. It has been recently reported that c-Src oxidation by NADPH
oxidase-derived ROS is crucial for c-Src and VEGF receptor 2 (VEGFR2) binding and activa-
tion of downstream c-Src-PI3K-Akt-eNOS signaling (Figure 2). Further oxidation of sulfinic
acid to sulfonic acid (-SO3H) is irreversible and does not participate in signal transduction
(Figure 2).
3.1.3. Hydroxyl anions
HO− is usually produced from H2O2 by free metals (Fenton reaction) or from the interaction
between water and excited O2. HO− is highly reactive with a very short lifespan, is promiscuous
in its interaction, and thus can cause sustained damage to DNA, amino acids, lipids, and
glucose moieties mostly due to irreversibility of its interaction with biological molecules. It is
thus considered a major contributor to “oxidative stress.”
3.1.4. Nitric oxide
It is considered to be the “golden” molecule for cardiovascular health, which is crucial in the
maintenance of the health of cardiac and vascular tissues. In EC, NO− is produced by the
enzyme eNOS and is involved in survival, growth, proliferation, and migration of vascular
ECs. It is very critical for the maintenance of a continuous EC layer throughout the cardiovas-
cular system. In fact, many of the critical functions carried out by EC are performed by NO−,
such as endothelium-dependent vasodilation (by activating cGMP pathway to decrease Ca2+
in vascular smooth cells, VSMC), prevention of adhesion of the anti-inflammatory cells to EC,
maintenance of blood fluidity (anticoagulant, anti-thrombotic, and profibrinolytic actions),
and anti-hypertrophic activity of EC through inhibition of VSMC proliferation and migration
(Figure 1). NO, though it possess all the properties of a ROS, is often not considered as ROS
by classical redox biologists. Interestingly, uncoupled eNOS may also generate superoxide.
3.1.5. Peroxynitrite
ONOO−is generated by interaction between O2•− and NO−. Like hydroxyl radical, peroxynitrite
is also highly reactive and damaging to biological molecules including protein/enzyme due to
its irreversible interaction. Thus, it is often considered as a marker for oxidative stress and/or
oxidative tissue damage. In cardiovascular system, in addition to tissues damages, increase
in ONOO− is considered to be an indicator of high ROS and low availability of NO−, since O2•
− interacts with and quenches NO−. Decrease availability of NO−, often marked by increase in
peroxynitrite levels, is considered to be responsible for endothelial dysfunction, i.e., reduced
vasorelaxation, often an initial marker for CVD.
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3.2. Subcellular sources of ROS
Biological sources of ROS are mitochondria (produced as a by-product of oxidative phosphor-
ylation), NADPH oxidases, cytochrome P450, xanthine oxidase, lipoxygenase, myeloperoxi-
dase, and uncoupled eNOS (Figure 3). While mitochondria act as the major source of ROS in
most cardiovascular cells including cardiomyocytes, NADPH oxidases are the major source
of intracellular ROS in vascular endothelium. EC derives most of its energy (ATP) from non-
mitochondrial glycolysis, rendering it (EC) less likely to have excess ROS from mitochondrial
source in physiological condition (Figure 3).
Figure 3. Subcellular sources of ROS include NADPH oxidase, mitochondria, peroxisome, lysosome, endoplasmic re-
ticulum (ER), and cytochrome P450. NAPDH oxidases (Nox) are usually present in the cell membrane and perinuclear
and ER membranes. Major species of ROS produced by NADPH oxidase is superoxide (O2−). Mitochondria produce
ROS as a by-product of respiration/oxidative phosphorylation; electrons leaked from the electron transport chain
(ETC), especially from Complexes I and III, produce superoxide in the mitochondrial matrix. Mitochondrial superox-
ide dismutase (MnSOD) converts superoxide to H2O2, which can then cross mitochondrial membrane to enter the cyto-
sol. Nox is also found on the ER.
3.2.1. NADPH oxidase
NADPH oxidase is a multisubunit, membrane-bound protein complex that catalyzes oxida-
tion of NADPH to NADP+ and H+, and in the process releases an electron. Molecular oxygen
accepts this released electron and becomes O2•−. There are several isoforms of NADPH oxi-
dases, such as Rac-1-dependent NADPH oxidase (it contains Nox2/gp91phox, Figure 2),
Nox1, Nox3, Nox4, and Nox5. All isoforms have been reported to be found in the cardiovas-
cular system except Nox3. With the exception of Nox4 (which is believed to release H2O2),
all NADPH oxidases produce superoxide. NADPH oxidase is a major source of ROS in vas-
cular endothelium and thus plays important roles in signal transduction in cardiovascular
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system in health and disease. It has been shown that ECs possess two distinct major signal-
ing pathways, redox-sensitive and redox-independent [24]. While PI3K-Akt-eNOS and Akt-
FOXO signaling pathways were shown to be NADPH oxidase-derived ROS-dependent,
PLCγ-MAPK-ERK signaling pathways were redox-independent in human coronary vascu-
lar ECs (Figure 4) [24]. Reduction in Nox-derived ROS resulted in inhibition of EC prolifera-
tion and migration [21, 25, 26]. Interestingly, recent findings further demonstrated that
above-physiological levels (i.e. twofold increase compared to basal levels) of EC-specific
Nox-derived ROS activated AMPK-eNOS signaling pathway in transgenic animals resulting
in EC-dependent coronary vasorelaxation [22]. Together, these findings suggest that
NADPH oxidase-derived ROS, both at the physiological and above-physiological levels, ex-
ert positive effects on EC health, growth, and function (Figure 4).
3.2.2. Mitochondria
Mitochondria play a major role in ROS generation in cardiovascular cells with one notable
exception in ECs. Electrons leaked from ETC during oxidative phosphorylation in mitochon-
dria produce O2•−. Efficient mitochondrial respiration produces less ROS, however, ineffi-
cient oxidative phosphorylation gives rise to excess ROS by leaking electrons from the
complexes I and III of the ETC. Mitochondrial antioxidant MnSOD (SOD2) plays a major
Figure 4. Coronary endothelium possesses two distinct signaling pathways: redox-sensitive PI3K-Akt-eNOS and PI3K-
Akt-forkhead (FOXO) signaling (left panel) and redox-independent PLCγ-PKC-MEK-ERK1/2 signaling pathway (right
panel).
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role in reducing mitochondrial ROS by catalyzing superoxide to H2O2; Gpx further catalyzes
H2O2 to molecular oxygen and water. Mitochondrial ROS may also increase due to increase
in NO, which has been reported to inhibit Complex-I and in turn increase superoxide forma-
tion by leaking electrons into the matrix of the mitochondria.
3.2.3. Xanthine oxidase
Sulfhydryl oxidation of xanthine dehydrogenase results in xanthine oxidase formation. XO
generates superoxide as a byproduct of the reaction where XO catalyzes the conversion of
hypoxanthine to xanthine and xanthine to uric acid. XO is believed to produce ROS, especial-
ly H2O2, in ischemic conditions where oxygen tension is low. However, in ischemia-reperfusion
injury, XO has been reported to be generating superoxide [27].
3.2.4. Lipoxygenase
Lipoxygenase plays an important role in hyperlipidemic state. It has been implicated in the
oxidation of polyunsaturated fatty acids and in the pathology of atherosclerotic plaque
formation and aortic aneurysm development.
3.2.5. Endothelial nitric oxide synthase
As aforementioned, eNOS generates NO. However, it can also produce ROS when uncoupled
due to reduced availability of substrates l-arginine and/or co-factor BH4. Peroxynitrite may
oxidize BH4, which in turn uncouple eNOS to form superoxide. Increased ROS is, thus,
believed to activate a feed forward loop for ROS generation by uncoupling of eNOS.
3.3. Antioxidant enzymes
ROS balance is extremely critical for signal transduction and optimal functions of the cells.
“Antioxidant enzymes” play an important role in redox balance. There are many cellular and
extracellular enzymes that participate in oxidant metabolism, several of these are evolutio-
narily conserved. The term “antioxidant” is a misnomer for some of the proteins such as
superoxide dismutase (SOD), which on one hand reduces the level of superoxide by converting
superoxide to H2O2, but on the other hand increases H2O2, and thus results in overall increase
in ROS levels. Thus, although it is called as antioxidant, SOD may well act like a pro-oxidation
enzyme by converting a transient and localized ROS (O2−) to stable H2O2, which can cross
membranes and thus can act farther away from its site of origin (paracrine effect).
3.3.1. Superoxide dismutases (SODs)
The very first step in regulating superoxide levels is catalyzed by this group of enzymes.
Superoxide is converted to H2O2 by SOD. Most cells in the body including ECs have three
isoforms of SOD, such as cytosolic SOD1 (Cu-Zn SOD), which catalyzes cytosolic superoxide
to H2O2. SOD1 knockout mice have been shown to have impaired EC-dependent vasodilation
[28]. In contrast, mitochondrial SOD2 (MnSOD) deletion was found to be embryonic lethal.
SOD2 is a nuclear gene which upon protein translation translocated to mitochondrial matrix.
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Heterozygous SOD2 mice demonstrated to have hypertension [29]. Excess ROS (e.g. ONOO)
may inactivate SOD2; nitrosylation of MnSOD by ONOO has been reported to inhibit the
antioxidant activity of the enzyme. Thus, increase in ONOO due to elevated ROS may result
in increased mitochondrial ROS by inhibiting MnSOD activity. The “extracellular” SOD3 (Cu/
ZnSOD) is a secreted protein which is localized in the outer part of the cell membrane. Deletion
of SOD3 is not lethal; however, defective neovascularization has been reported in SOD3 null
animals [30].
3.3.2. Glutathione peroxidase (Gpx)
Gpx catalyzes the conversion of H2O2 to water. Gpx is more abundantly expressed in cardio-
vascular cells including EC than catalase. It is also a major antioxidant protein in the mito-
chondria and is believed to have more critical role than catalase in regulating endothelial ROS.
Gpx null animals have endothelial dysfunction [31]. It has also been reported to have severe
ischemic-reperfusion injury [32] and defective angiogenesis compared to wild-type control
[33].
3.3.3. Catalase
Functionally, catalase is similar to Gpx as it converts H2O2 to molecular oxygen and water.
Structurally, catalase is a 4-heme containing enzyme. Knockout of catalase is not lethal.
3.3.4. Peroxidoredoxin (Prx)
Prx is a group of enzymes abundantly expressed in cardiovascular system. Functionally, they
are similar to Gpx. Probably the most important role of Prx is to protect hemoglobin (Hb) in
red blood cells (erythrocytes) where a lack of Prx has been shown to be associated with
oxidation of Hb resulting in anemia.
3.3.5. Thioredoxin (Trx)
There are two isoforms of Trx present in the cardiovascular tissues, Trx-1 being present in the
cytosol and Trx-2 in the mitochondria. They catalyze thiol-disulfide exchange on the cysteine
residues present in the protein and thus convert the oxidized thiols of the proteins to their
reduced (SH) forms. This protective action by reducing oxidized pools of proteins in the cells
is crucial for redox balance. Overexpression of Trx has been shown to have protective effects
against oxidative stress on cardiovascular function [34].
4. Understanding subcellular ROS is critical in CVD
It is obvious from the aforementioned discussion that endogenous ROS levels in specific
subcellular compartments regulate certain signaling pathways, survival, proliferation, and
pathophysiology in cardiovascular tissues. Precise understanding of the spatial (i.e. at different
subcellular locations such as in the cytosol, mitochondria) and temporal role of redox (i.e. changes
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in the role of ROS with time) to selectively activate downstream signaling pathways, maintain
an intact and continuous EC layer throughout the cardiovascular system, maintain vasodila-
tion in resistance arterioles, and induce a proangiogenic environment in ischemic myocardium
is critical for the development of future therapeutic modalities for microvascular disease. In
case of redox regulation, failure of the “all or none” approach (e.g. using global antioxidants
as in the HOPE trial) also points to the end of an era that has treated any increase in cellular
ROS levels as “deleterious.” Instead, it is high time to consider ROS as signaling molecules,
increase of which may also have “beneficial” effects during a cellular or cardiovascular crisis
such as inflammation, ischemia-reperfusion, myocardial infarction, or other cardiovascular
injuries including stroke. For example, an initial increase in endothelial ROS by Rac1-depend-
ent NADPH oxidase (Nox) may have positive effects on EC survival during a time of crisis;
increase in EC-specific Nox-ROS has been shown to activate a survival pathway (e.g. activation
of pro-survival kinase AMPK) and improve endothelial function (coronary vasodilation) by
inducing AMPK-eNOS-NO [22]. Thus, it is of utmost importance to understand the roles of
modulation (increase or decrease) of subcellular (cytosolic vs. mitochondrial vs. peroxisomal/
lysosomal) ROS levels in health and disease.
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